01/04/22 7:00 AMNasdaq : PRLD conferencesPrelude Therapeutics to Present at the H.C. Wainwright BioConnect Virtual ConferencePrelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will present at the H.C Wainwright BioConnect Virtual Conference, being held on January 10-13,RHEA-AIneutral
11/23/21 7:00 AMNasdaq : PRLD conferencesPrelude Therapeutics to Participate at the 4th Annual Evercore ISI HealthCONx ConferencePrelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the 4 th Annual Evercore ISI HealthCONx ConferenceRHEA-AIneutral
11/12/21 8:00 AMNasdaq : PRLD earningsPrelude Therapeutics Announces Third Quarter 2021 Financial Results and Operations UpdatePRT543 and PRT811 Demonstrate Favorable Safety Profile, Tolerability and Evidence of Preliminary Clinical Activity in Phase 1 Dose Escalation in Unselected Patients Phase 1 Dose Expansion Ongoing in Biomarker-Selected Solid Tumor and Hematologic Malignancy Expansion Cohorts for PRT543; DoseRHEA-AIneutral
11/08/21 9:00 AMNasdaq : PRLD Prelude Therapeutics Announces IND Clearance for PRT2527, a Highly Selective CDK9 InhibitorPrelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that the United States Food and DrugRHEA-AIneutral
10/07/21 9:00 AMNasdaq : PRLD Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics– Lead oral PRMT5 inhibitors PRT543 and PRT811 demonstrate favorable safety profile, evidence of preliminary clinical activity including durable responses and high levels of target inhibition of PRMT5 in Phase 1 dose escalation in unselected patients – – CDK9 inhibitor PRT2527 demonstrates strongRHEA-AIneutral
09/02/21 7:00 AMNasdaq : PRLD conferencesPrelude Therapeutics Announces Participation at Two Upcoming Virtual Investor ConferencesPrelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: Morgan Stanley 19 th Annual GlobalRHEA-AIneutral
08/12/21 7:30 AMNasdaq : PRLD earningsPrelude Therapeutics Announces Second Quarter 2021 Financial Results and Operations Update- Data from Dose Escalation Portion of Phase 1 Trials of Lead Oral PRMT5 Inhibitors PRT543 and PRT811 to be Presented in 4Q21 – - Enrollment Ongoing in Multiple Expansion Cohorts in Phase 1 Trial of PRT543; Dose Expansion Portion of Phase 1 Trial of PRT811 Expected to Commence in 3Q21 – - DoseRHEA-AIneutral
07/19/21 7:00 AMNasdaq : PRLD managementPrelude Therapeutics Announces Appointment of Martin Babler to its Board of DirectorsPrelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the appointment of Martin Babler to its Board of Directors. Mr. Babler brings to Prelude over 25 years of pharmaceutical and biotechRHEA-AIneutral
06/02/21 7:00 AMNasdaq : PRLD conferencesPrelude Therapeutics Announces Participation at Two Upcoming Virtual Investor ConferencesPrelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team will participate in two upcoming virtual investor conferences: 42 nd Annual Goldman Sachs GlobalRHEA-AIneutral
05/11/21 7:30 AMNasdaq : PRLD earningsPrelude Therapeutics Announces First Quarter 2021 Financial Results and Operations Update- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 - - Dose Escalation Ongoing in Phase 1 Trial of OralRHEA-AIneutral